Your browser is no longer supported. Please, upgrade your browser.
SAGE Sage Therapeutics, Inc. daily Stock Chart
Sage Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.06 Insider Own1.30% Shs Outstand48.93M Perf Week-3.14%
Market Cap8.06B Forward P/E- EPS next Y-11.24 Insider Trans-21.80% Shs Float48.93M Perf Month8.05%
Income-372.90M PEG- EPS next Q-3.26 Inst Own98.90% Short Float8.75% Perf Quarter20.72%
Sales90.30M P/S89.26 EPS this Y-14.10% Inst Trans0.60% Short Ratio8.04 Perf Half Y36.99%
Book/sh18.41 P/B8.95 EPS next Y13.20% ROA-35.30% Target Price200.44 Perf Year-2.42%
Cash/sh18.86 P/C8.74 EPS next 5Y13.10% ROE-37.40% 52W Range79.88 - 177.14 Perf YTD71.97%
Dividend- P/FCF- EPS past 5Y-60.30% ROI-45.60% 52W High-7.01% Beta2.92
Dividend %- Quick Ratio11.00 Sales past 5Y- Gross Margin- 52W Low106.22% ATR5.97
Employees637 Current Ratio11.00 Sales Q/Q- Oper. Margin- RSI (14)54.30 Volatility4.36% 3.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-96.40% Profit Margin- Rel Volume2.03 Prev Close161.47
ShortableYes LT Debt/Eq0.00 EarningsFeb 19 BMO Payout- Avg Volume532.20K Price164.73
Recom1.60 SMA200.82% SMA504.32% SMA20017.82% Volume1,078,129 Change2.02%
Dec-14-18Initiated Wolfe Research Outperform
Oct-11-18Initiated Oppenheimer Outperform $170
Aug-07-18Reiterated Stifel Buy $198 → $239
Aug-06-18Initiated Piper Jaffray Overweight $206
Jun-06-18Initiated Ladenburg Thalmann Buy $230
Mar-26-18Resumed Canaccord Genuity Buy $210
Feb-26-18Initiated Morgan Stanley Overweight
Dec-08-17Reiterated Needham Buy $100 → $193
Dec-08-17Reiterated Canaccord Genuity Buy $140 → $191
Dec-07-17Reiterated Chardan Capital Markets Buy $140 → $225
Nov-10-17Upgrade Chardan Capital Markets Neutral → Buy $60 → $140
Nov-10-17Reiterated Needham Buy $86 → $100
Oct-06-17Resumed Goldman Buy $87
Sep-15-17Initiated RBC Capital Mkts Outperform $117
Sep-13-17Reiterated Needham Buy $95 → $86
Aug-09-17Resumed Stifel Buy $104
May-16-17Initiated Needham Buy $82
May-12-17Initiated BofA/Merrill Buy $85
Feb-22-17Downgrade H.C. Wainwright Buy → Neutral $56 → $76
Feb-14-17Upgrade Chardan Capital Markets Sell → Neutral $60
Apr-18-19 04:30PM  Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019 Business Wire
Apr-03-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-01-19 09:25AM  The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks
Mar-25-19 08:49AM  5 biotech stocks that could be the next big winners MarketWatch
Mar-23-19 10:02AM  2 Biotech Takeout Targets Perfect for Biogen Motley Fool
Mar-21-19 09:59AM  A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me
06:53AM  Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout MarketWatch
Mar-20-19 10:16PM  Is Sage Therapeutics a Good Stock to Buy Now? Motley Fool
08:35PM  Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)
07:08PM  Sage Therapeutics CEO: Getting the first postpartum depre... CNBC Videos
04:18PM  This Biotech Stock Grabbed A First In Depression So What's Next? Investor's Business Daily
12:44PM  The Late Morning Rundown: March 20, 2019 CNBC Videos
11:21AM  Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know Benzinga
11:01AM  General Mills posts strong quarter, concerns at FedEx, done deal for Disney Yahoo Finance
10:50AM  FDA approves postpartum depression drug created by Sage Therapeutics Yahoo Finance Video
10:43AM  Sage Stock Pops on FDA Approval for Postpartum Depression Drug InvestorPlace
09:40AM  Stocks Lose Ground Ahead Of Federal Reserve; FedEx, Monster Tumble Investor's Business Daily
08:00AM  This Postpartum-Depression Drug Has Unusual Potential Bloomberg
07:38AM  FedEx, Federal Reserve, Google, AMD, Sage Therapeutics - 5 Things You Must Know
Mar-19-19 08:38PM  [$$] Postpartum Depression Drug Gets FDA Approval The Wall Street Journal
07:06PM  FDA approves drug for treating postpartum depression Associated Press
07:00PM  Sage gets U.S. approval for first postpartum depression therapy Reuters
07:00PM  Sage Therapeutics Announces FDA Approval of ZULRESSO (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression Business Wire
06:53PM  FDA approves first drug specifically to treat postpartum depression MarketWatch
06:43PM  Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug
05:58PM  Sage Therapeutics stock rises after FDA approves first postpartum depression drug Zulresso CNBC
05:53PM  FDA approves Sage's first-ever treatment for postpartum depression American City Business Journals
05:44PM  Sage gets U.S. approval for first postpartum depression therapy Reuters
02:30PM  FedEx Sinks After Hours; Smartsheet Dives, Sage Rises
Mar-18-19 07:00AM  Market Morning: Black Box Details, Brexit Referendum 2, Postpartum Drug, Oil Short Squeeze? Market Exclusive
Mar-07-19 04:53PM  Why News From J&J, Allergan Could Be A Boon For This Biotech Stock Investor's Business Daily
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
Mar-05-19 07:20AM  Market Trends Toward New Normal in Macy's, Comerica, JetBlue Airways, Intersect ENT, Stanley Black & Decker, and Sage Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-27-19 04:01PM  Sage Therapeutics Announces Closing of $575 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares Business Wire
Feb-25-19 09:05PM  Sage Therapeutics Prices Public Offering of Common Stock Business Wire
05:22PM  Stocks making the biggest moves after hours: Etsy, Hertz, Shake Shack and more CNBC
04:01PM  Sage Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Feb-20-19 09:43AM  Edited Transcript of SAGE earnings conference call or presentation 19-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-19-19 02:22PM  Sage Therapeutics Inc (SAGE) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:30AM  Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress Business Wire
06:00AM  SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-17-19 08:14AM  FOMC minutes, Walmart earnings What to know in the week ahead Yahoo Finance
Feb-14-19 03:30PM  Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily
10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
Feb-10-19 08:20PM  Here's Why Sage Therapeutics Gained 48.9% in January Motley Fool
Feb-08-19 07:50AM  Factors of Influence in 2019, Key Indicators and Opportunity within New Relic, Clean Harbors, Sage Therapeutics, Accelerate Diagnostics, Fortinet, and Colfax New Research Emphasizes Economic Growth GlobeNewswire
Feb-07-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-05-19 06:30AM  Sage Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 19, 2019 Business Wire
Jan-31-19 02:45PM  Here are Boston-area biotechs pursuing Parkinson's treatments American City Business Journals +7.49%
Jan-24-19 09:00AM  Three Companies Using AI and Innovation to Lead Healthcare Sector ACCESSWIRE
Jan-23-19 07:00AM  Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors Business Wire
Jan-17-19 11:31AM  Ligand (LGND) Takes a Hit on Citron's Negative Research Report Zacks
06:55AM  Citron Says Ligand Has 80% Downside in Explosive Note Investopedia
Jan-16-19 04:18PM  Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It Investor's Business Daily
08:05AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jan-15-19 08:00PM  3 Small-Cap Stocks With Big-Cap Potential Motley Fool
04:18PM  Here's How The Government Shutdown Will Affect These Medical Stocks Investor's Business Daily
Jan-11-19 07:46AM  The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference Motley Fool
Jan-10-19 03:23PM  3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year Motley Fool +5.34%
Jan-09-19 03:07PM  Eyeing FDA approval, Sage lays out strategy for dual postpartum depression drugs American City Business Journals -7.40%
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 12:38PM  Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week Motley Fool -6.99%
Jan-07-19 06:49PM  Biotech Stocks Post Double-Digit Gains in Monday Surge +42.68%
04:56PM  What Happened in the Stock Market Today Motley Fool
01:27PM  Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results MarketWatch
11:45AM  Why Sage Therapeutics Is Skyrocketing Today Motley Fool
10:40AM  SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results
07:35AM  Report: Developing Opportunities within General Mills, Philip Morris International, Sage Therapeutics, CNA Financial, Hess, and AutoNation Future Expectations, Projections Moving into 2019 GlobeNewswire
07:00AM  Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference Business Wire
06:50AM  Today's Research Reports on Trending Tickers: Amarin Corporation and Sage Therapeutics ACCESSWIRE
06:31AM  Pill for postpartum depression by Cambridge's Sage succeeds in late-stage trial American City Business Journals
06:00AM  Sage's oral postpartum depression treatment succeeds in late-stage study Reuters
06:00AM  Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression Business Wire
Jan-04-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire +9.16%
Jan-03-19 09:16AM  Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options Zacks
Dec-27-18 06:30AM  Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 Business Wire
Dec-24-18 01:13PM  Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019 Investor's Business Daily
Dec-20-18 01:08PM  DAFNA Capital Management Return, AUM and Holdings Insider Monkey -8.86%
09:46AM  Has Sage Therapeutics, Inc. (NASDAQ:SAGE) Got Enough Cash? Simply Wall St.
Dec-14-18 07:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune ACCESSWIRE
Dec-12-18 04:12PM  Here's Why Marinus Pharmaceuticals Is Sinking Today Motley Fool
Dec-10-18 03:56AM  Hedge Funds Are Selling SAGE Therapeutics Inc (SAGE) Insider Monkey
Dec-05-18 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-30-18 06:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics ACCESSWIRE
Nov-29-18 07:45AM  New Research: Key Drivers of Growth for Upland Software, VICI Properties, Sage Therapeutics, Jack Henry & Associates, T2 Biosystems, and Tata Motors Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-26-18 07:00AM  Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Sage Therapeutics ACCESSWIRE
Nov-21-18 06:30AM  Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference Business Wire
Nov-20-18 07:30AM  Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO (brexanolone) Injection Business Wire
Nov-17-18 03:53PM  Edited Transcript of SAGE earnings conference call or presentation 6-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE
Nov-12-18 05:54PM  Stocks making the biggest moves after hours: PG&E, Eventbrite and more CNBC -7.26%
Nov-07-18 04:01PM  Sage Therapeutics to Present at Stifel 2018 Healthcare Conference Business Wire
Nov-06-18 06:30AM  Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress Business Wire
Nov-05-18 07:00AM  Todays Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics ACCESSWIRE -8.28%
06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-02-18 04:53PM  FDA panel recommends Sage's postpartum depression treatment Reuters
04:45PM  Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO (brexanolone) Injection for Treatment of Postpartum Depression Business Wire
03:03PM  FDA committee recommends Sage's postpartum depression drug American City Business Journals
07:09AM  Sage Therapeutics shares halted ahead of regulatory meeting on post-partum treatment MarketWatch
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAUL STEVEN MDirectorMar 21Sale161.047,8791,268,824122,400Mar 22 04:22 PM
PAUL STEVEN MDirectorMar 20Sale161.2956,6469,136,582130,279Mar 20 08:47 PM
PAUL STEVEN MDirectorMar 18Sale161.053,775607,977186,925Mar 20 08:47 PM
IGUCHI KIMICFO & TreasurerMar 08Option Exercise0.454,7232,1256,136Mar 11 05:03 PM
IGUCHI KIMICFO & TreasurerMar 01Sale156.9325,5634,011,6021,413Mar 01 04:46 PM
PAUL STEVEN MDirectorFeb 25Sale161.002,000322,00070,900Feb 27 05:48 PM
PAUL STEVEN MDirectorFeb 19Sale161.621,543249,37372,900Feb 20 07:55 AM
PAUL STEVEN MDirectorFeb 15Sale161.0249,4617,964,21074,443Feb 20 07:55 AM
Kanes StephenChief Medical OfficerFeb 08Sale150.0022,9483,442,200941Feb 08 05:08 PM
FRATES JAMES MDirectorJan 23Option Exercise8.927,50066,90011,735Jan 24 05:44 PM
FRATES JAMES MDirectorJan 23Sale134.817,5001,011,0754,235Jan 24 05:44 PM
JONAS JEFFREY MPresident & CEOJan 09Option Exercise0.4510,0004,50062,115Jan 10 05:16 PM
IGUCHI KIMICFO & TreasurerJun 19Option Exercise0.4580036026,826Jun 20 04:07 PM
FRATES JAMES MDirectorMay 08Option Exercise8.927,00062,44012,000May 08 04:51 PM
FRATES JAMES MDirectorMay 08Sale154.007,0001,078,0005,000May 08 04:51 PM
IGUCHI KIMICFO & TreasurerApr 25Sale140.7511,0181,550,81038,345Apr 25 05:44 PM
IGUCHI KIMICFO & TreasurerApr 24Sale142.845,000714,18549,363Apr 25 05:44 PM
IGUCHI KIMICFO & TreasurerApr 23Sale144.4812,1351,753,30254,363Apr 25 05:44 PM